论文部分内容阅读
目的:观察外科新三联疗法(外科换药-威伐激光-成纤维细胞生长因子)治疗糖尿病足溃疡的临床疗效和安全性。方法:将57例糖尿病足溃疡患者随机分为2组。对照组28例,采用外科换药辅以成纤维细胞生长因子外敷治疗;治疗组29例,在对照组治疗的基础上配合威伐激光照射治疗。疗程为8周,观察两组患者的治疗有效率、愈合时间和不良反应的发生情况。结果:治疗组和对照组的有效率分别为86.21%、57.14%,治疗组显著高于对照组(P<0.05);且治疗组溃疡的愈合时间(39.40±2.24天)较对照组(50.67±2.31天)明显缩短(P<0.01)。此外,两组患者均无明显的不良反应发生。结论:外科新三联疗法(外科换药-威伐激光-成纤维细胞生长因子)是治疗糖尿病足溃疡的有效方法,且安全性好。
Objective: To observe the clinical efficacy and safety of surgical new triple therapy (surgical dressing - Wafar laser - fibroblast growth factor) in the treatment of diabetic foot ulcer. Methods: 57 cases of diabetic foot ulcer were randomly divided into two groups. Control group of 28 cases, using surgical dressing with fibroblast growth factor external application; treatment group of 29 cases, in the control group based on the treatment with the Waring laser irradiation treatment. The course of treatment was 8 weeks. The treatment efficiency, healing time and adverse reactions of the two groups were observed. Results: The effective rates of the treatment group and the control group were 86.21% and 57.14% respectively, which were significantly higher in the treatment group than in the control group (P <0.05). The healing time of the ulcer in the treatment group (39.40 ± 2.24 days) 2.31 days) was significantly shorter (P <0.01). In addition, no adverse reactions occurred in both groups. Conclusion: The new surgical triple therapy (surgical dressing - Wafar laser - fibroblast growth factor) is an effective method for the treatment of diabetic foot ulcers, and good safety.